United States · FDA National Drug Code directory
Liraglutide
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 14403-3400_2854c47e-c069-07d7-e063-6394a90a50eb
- Product NDC
- 14403-3400
- Form
- INJECTION, SOLUTION
- Composition / generic term
- Liraglutide
- Labeler
- Hybio Pharmaceutical Co., Ltd. (Pingshan Factory)
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20241224
- Source listing expiry
- 20261231
Source-listed ingredients
- LIRAGLUTIDE — 18 mg/3mL
These values do not establish equivalence or a dose recommendation.
Packages
- 2 SYRINGE, PLASTIC in 1 CARTON (14403-3400-2) / 3 mL in 1 SYRINGE, PLASTIC (14403-3400-1) · 14403-3400-2
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →